Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more
Diamyd Medical AB (publ) - Asset Resilience Ratio
Diamyd Medical AB (publ) (DMYD-B) has an Asset Resilience Ratio of 77.10% as of November 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Diamyd Medical AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Diamyd Medical AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr213.33 Million | 70.53% |
| Short-term Investments | Skr19.85 Million | 6.56% |
| Total Liquid Assets | Skr233.19 Million | 77.10% |
Asset Resilience Insights
- Very High Liquidity: Diamyd Medical AB (publ) maintains exceptional liquid asset reserves at 77.10% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Diamyd Medical AB (publ) Industry Peers by Asset Resilience Ratio
Compare Diamyd Medical AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Diamyd Medical AB (publ) (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Diamyd Medical AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-08-31 | 78.60% | Skr277.19 Million | Skr352.64 Million | +17.62pp |
| 2024-08-31 | 60.99% | Skr132.37 Million | Skr217.04 Million | -0.70pp |
| 2023-08-31 | 61.69% | Skr126.96 Million | Skr205.81 Million | -5.82pp |
| 2022-08-31 | 67.51% | Skr159.67 Million | Skr236.52 Million | -1.68pp |
| 2021-08-31 | 69.19% | Skr139.38 Million | Skr201.44 Million | -6.97pp |
| 2020-08-31 | 76.16% | Skr68.36 Million | Skr89.76 Million | -0.27pp |
| 2019-08-31 | 76.43% | Skr56.71 Million | Skr74.20 Million | -3.80pp |
| 2018-08-31 | 80.23% | Skr44.11 Million | Skr54.98 Million | -6.67pp |
| 2017-08-31 | 86.90% | Skr85.72 Million | Skr98.65 Million | +3.79pp |
| 2016-08-31 | 83.11% | Skr31.40 Million | Skr37.78 Million | +55.24pp |
| 2015-08-31 | 27.87% | Skr13.00 Million | Skr46.65 Million | +6.39pp |
| 2014-08-31 | 21.48% | Skr10.96 Million | Skr51.02 Million | -29.70pp |
| 2012-08-31 | 51.18% | Skr215.85 Million | Skr421.74 Million | -2.29pp |
| 2011-08-31 | 53.48% | Skr277.86 Million | Skr519.60 Million | -- |